KG&L Capital Management’s GSK GSK Stock Holding History

KG&L Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$554K	Buy	10,568 +5,718	+118%	+$302K	0.33%	82
2026 Q1	$258K	Sell	4,850 -7,723	-61%	-$419K	0.18%	108
2025 Q4	$610K	Sell	12,573 -170	-1%	-$7.93K	0.15%	122
2025 Q3	$546K	Sell	12,743 -1,265	-9%	-$49.4K	0.15%	121
2025 Q2	$536K	Buy	14,008 +1,353	+11%	+$51.7K	0.16%	111
2025 Q1	$488K	Sell	12,655 -376	-3%	-$13.8K	0.16%	124
2024 Q4	$441K	Sell	13,031 -3,654	-22%	-$132K	0.14%	129
2024 Q3	$679K	Buy	16,685 +5,104	+44%	+$209K	0.22%	98
2024 Q2	$444K	Sell	11,581 -33,002	-74%	-$1.39M	0.15%	131
2024 Q1	$1.91M	Sell	44,583 -3,662	-8%	-$151K	0.76%	29
2023 Q4	$1.79M	Sell	48,245 -1,106	-2%	-$39.7K	0.75%	28
2023 Q3	$1.79M	Sell	49,351 -759	-2%	-$26.9K	0.86%	25
2023 Q2	$1.79M	Sell	50,110 -190	-0.4%	-$6.82K	0.86%	24
2023 Q1	$1.79M	Buy	50,300 +1,636	+3%	+$57.2K	0.94%	24
2022 Q4	$1.71M	Buy	+48,664	New	+$1.62M	0.99%	23
2022 Q3	–	Sell	-23,767	Closed	-$1.29M	–	131
2022 Q2	$1.29M	Buy	23,767 +78	+0.3%	+$4.31K	0.7%	35
2022 Q1	$1.29M	Buy	23,689 +180	+0.8%	+$9.78K	0.54%	49
2021 Q4	$1.3M	Sell	23,509 -634	-3%	-$33K	0.52%	56
2021 Q3	$1.15M	Sell	24,143 -3,394	-12%	-$170K	0.51%	55
2021 Q2	$1.37M	Buy	27,537 +1,095	+4%	+$52.6K	0.62%	41
2021 Q1	$1.18M	Buy	26,442 +7,476	+39%	+$339K	0.59%	42
2020 Q4	$872K	Buy	18,966 +1,524	+9%	+$70K	0.48%	51
2020 Q3	$820K	Buy	17,442 +5,834	+50%	+$292K	0.51%	48
2020 Q2	$591K	Buy	11,608 +450	+4%	+$23.1K	0.45%	53
2020 Q1	$528K	Buy	11,158 +5,496	+97%	+$293K	0.53%	51
2019 Q4	$332K	Buy	5,662 +504	+10%	+$28K	0.28%	72
2019 Q3	$275K	Buy	5,158 +1,004	+24%	+$51.6K	0.25%	76
2019 Q2	$207K	Buy	+4,154	New	+$208K	0.2%	85

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

KG&L Capital Management's GSK Position: Q2 2026 in Review

KG&L Capital Management increased its GSK (GSK) stake by 118% in Q2 2026, buying an estimated $302K and bringing the position to 10,568 shares worth $554K. The position accounts for 0.33% of the portfolio, ranked #82.

KG&L Capital Management first reported a position in GSK in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.91M in Q1 2024. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

KG&L Capital Management held 10,568 shares of GSK worth $554K as of Q2 2026.
KG&L Capital Management bought 5,718 GSK shares in Q2 2026, an estimated $302K.
GSK made up 0.33% of KG&L Capital Management's portfolio in Q2 2026, its #82 holding.
KG&L Capital Management first reported a position in GSK in Q2 2019 and has held it in 28 quarters since.
KG&L Capital Management's GSK position peaked at $1.91M in Q1 2024.
1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on KG&L Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.